When a heart attack happens, part of the heart muscle is cut off from its blood supply. The damage that follows depends a lot on how quickly the tissue can rebuild its network of tiny blood vessels. Without that rebuilding process, called angiogenesis, the heart struggles to recover. Scientists have long searched for the molecular signals that drive or block this repair.
A study published in Nature Communications identified a protein called PCSK5 as a surprisingly important player in that process. Researchers found that PCSK5 is produced by the cells lining blood vessel walls, known as endothelial cells, and that its levels rise both in patients who have had a heart attack and in mouse models of the injury. More importantly, the study traced a clear chain of events from PCSK5 activity to new vessel growth and improved heart function.
What PCSK5 is and where it works
PCSK5 stands for proprotein convertase subtilisin/kexin 5. That is a long name for a type of enzyme whose job is to cut other proteins at specific points, in the same way scissors trim a long thread. By making those precise cuts, PCSK5 can switch other proteins from an inactive form into a working one. The enzyme belongs to a family of convertases already known to scientists for roles in cholesterol handling and hormone processing.
Earlier research established that PCSK5 is necessary for normal heart development in the embryo. What the new study asked was whether PCSK5 also matters in the adult heart when tissue is damaged. To answer that, the research team measured PCSK5 in the blood of people who had experienced a heart attack and examined its expression inside endothelial cells taken from those patients.
Findings in patients and animal models
The study found that plasma concentrations of PCSK5 were elevated in heart-attack patients compared with healthy controls. Notably, higher levels showed a statistical relationship with better recovery of cardiac function, suggesting the protein may carry information about how well a damaged heart is repairing itself. The researchers also confirmed, using tissue samples from human hearts, that PCSK5 expression was specifically increased inside endothelial cells in the infarcted area.
To test what the protein actually does, the team used mice in which the Pcsk5 gene had been selectively turned off only in endothelial cells. Those mice showed poorer angiogenesis and weaker cardiac recovery after an experimentally induced heart attack. They also healed more slowly from a separate model of reduced blood flow in the hind limb. The opposite experiment, delivering extra Pcsk5 specifically to endothelial cells, improved both the density of new blood vessels and the pumping function of the heart in the post-infarct period.
The molecular mechanism behind the effect
The most precise part of the study focused on exactly how PCSK5 encourages new blood vessels to form. The researchers found that PCSK5 directly cleaves a well-known growth factor called VEGFA, which stands for vascular endothelial growth factor A. VEGFA is already recognized as one of the main molecular signals that instructs cells to sprout new vessels. The problem is that VEGFA is often produced in a precursor form that is not yet fully active.
PCSK5 appears to cut VEGFA at a specific site, converting it into the version that activates its signaling pathway more effectively. The study identified two amino acid residues on the PCSK5 protein itself, at positions 158 and 164, as critical to that cleavage reaction. When those residues were altered, the protein lost its ability to activate VEGFA and the pro-angiogenic effect disappeared. This points to a precise structural interaction, not a general or nonspecific effect.
Connection to a glucagon-like peptide-1 receptor agonist
One section of the study drew particular interest. The researchers tested whether a glucagon-like peptide-1 receptor agonist, a class of compound originally developed for blood sugar regulation, influenced this PCSK5 pathway. In the mouse heart-attack model, treatment with a compound from that drug class increased blood vessel density and improved cardiac function. When the researchers then removed endothelial Pcsk5 from those same mice, a meaningful portion of that benefit was lost.
The result suggests that the cardiovascular effects observed with that class of compound may operate partly through increasing PCSK5 activity in endothelial cells, not only through the metabolic pathways those compounds are traditionally associated with. The authors describe this as a partial mechanism, meaning other pathways are also involved, and they are careful not to claim PCSK5 is the whole story.
Significance and limitations
From a scientific standpoint, the study identifies PCSK5 as a secreted pro-angiogenic factor with a clearly described substrate, a measurable clinical correlate, and a testable genetic model. That combination makes it a reasonably strong candidate for further investigation as a target in ischemic disease research.
The study was conducted predominantly in male mice, which the authors acknowledge as a limitation. Whether the same biology operates equally in females, and whether plasma PCSK5 will prove to be a reliable biomarker in larger patient populations, are questions that future work will need to address. The research also does not test delivery of the protein therapeutically in humans, so the gap between the mouse findings and any potential clinical application remains substantial. As with most single studies, independent replication will be an important next step.
Broader context in vascular biology research
Angiogenesis after ischemic injury has been a target of investigation for decades. Many approaches have focused on delivering VEGFA directly or stimulating its receptor. The PCSK5 finding adds a layer upstream of that: an endogenous enzyme that fine-tunes how much active VEGFA is available in the local tissue environment. That kind of upstream regulator can sometimes be more tractable as a research target because it offers a natural point of control rather than flooding a system with a growth signal.
The study also contributes to a growing picture of how the proprotein convertase family does more than regulate lipid metabolism. Earlier members of this family, particularly the one involved in cholesterol handling through LDL receptors, have already changed clinical cardiology. PCSK5, sitting on a different branch of the same enzyme family, may turn out to be relevant to the structural repair side of cardiac biology rather than the lipid side. The literature suggests these distinctions matter for how researchers design future interventional studies.
